Zoetis Inc. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
Zoetis Inc. (ZTS) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $10.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-06
- Zoetis Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was $17.00M, a 48.48% decline year-over-year.
- Zoetis Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was $33.00M.
- Zoetis Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was -$6.00M.
- Zoetis Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2023-03-31 was -$3.00M, a 175.00% decline year-over-year.
- Zoetis Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was $39.00M.
- Zoetis Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$32.00M.
- Zoetis Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was -$7.00M.
- Zoetis Inc. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2022 was -$29.00M.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $10.00M 10-Q · filed 2026-08-06 | |||||
| 2026-03-31 | $17.00M 10-Q · filed 2026-05-07 | |||||
| 2025-12-31 | $39.00M 10-K · filed 2026-02-12 | |||||
| 2025-09-30 | $43.00M 10-Q · filed 2025-11-04 | |||||
| 2025-06-30 | $54.00M 10-Q · filed 2026-08-06 | $38.00M 10-Q · filed 2025-08-05 | ||||
| 2025-03-31 | $33.00M 10-Q · filed 2026-05-07 | -$1.00M 10-Q · filed 2025-05-06 | ||||
| 2024-12-31 | -$32.00M 10-K · filed 2026-02-12 | |||||
| 2024-09-30 | -$19.00M 10-Q · filed 2025-11-04 | |||||
| 2024-06-30 | -$14.00M 10-Q · filed 2025-08-05 | |||||
| 2024-03-31 | -$6.00M 10-Q · filed 2025-05-06 | |||||
| 2023-12-31 | -$7.00M 10-K · filed 2026-02-12 | |||||
| 2023-09-30 | -$4.00M 10-Q · filed 2024-11-04 | |||||
| 2023-06-30 | -$4.00M 10-Q · filed 2024-08-06 | |||||
| 2023-03-31 | -$3.00M 10-Q · filed 2024-05-02 | |||||
| 2022-12-31 | -$29.00M 10-K · filed 2025-02-13 | |||||
| 2022-09-30 | -$20.00M 10-Q · filed 2023-11-02 | |||||
| 2022-06-30 | -$2.00M 10-Q · filed 2023-08-08 | |||||
| 2022-03-31 | $4.00M 10-Q · filed 2023-05-04 | |||||
| 2021-12-31 | -$12.00M 10-K · filed 2024-02-13 | |||||
| 2021-09-30 | $0.00 10-Q · filed 2022-11-03 | |||||
| 2021-06-30 | $4.00M 10-Q · filed 2022-08-04 | |||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-05 | |||||
| 2020-12-31 | -$7.00M 10-K · filed 2023-02-14 | |||||
| 2020-09-30 | -$13.00M 10-Q · filed 2021-11-04 | |||||
| 2020-06-30 | -$19.00M 10-Q · filed 2021-08-05 | |||||
| 2020-03-31 | -$6.00M 10-Q · filed 2021-05-06 | |||||
| 2019-12-31 | -$8.00M 10-K · filed 2022-02-15 | |||||
| 2019-09-30 | -$8.00M 10-Q · filed 2020-11-05 | |||||
| 2019-06-30 | -$3.00M 10-Q · filed 2020-08-06 | |||||
| 2019-03-31 | $3.00M 10-Q · filed 2020-05-06 | |||||
| 2018-12-31 | -$26.00M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |